Skip to main content

Table 4 Correlations between antibody levels in serum (upper part) and IC (lower part) vs. SLEDAI-2K in 55 belimumab-treated SLE patients

From: Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus

 

Months

dsDNA

Histone

Rib P

PCNA

SSA/Ro52

SSA/Ro60

SSB/La

Sm

U1

RNP

Sm-U1

RNP

Serum

0

0.350 (0.010)

0.036 (0.798)

0.230 (0.098)

0.059 (0.675)

− 0.086 (0.541)

− 0.077 (0.582)

− 0.082 (0.561)

0.272 (0.049)

0.105 (0.454)

0.235 (0.091)

0–3

0.586 (0.723)

− 0.076 (0.644)

0.223 (0.173)

0.253 (0.120)

0.156 (0.344)

0.326 (0.105)

0.210 (0.200)

0.139 (0.398)

0.264 (0.104)

0.181 (0.272)

0–6

0.055 (0.776)

0.009 (0.963)

0.206 (0.283)

− 0.253 (0.204)

− 0.128 (0.507)

0.076 (0.696)

− 0.175 (0.364)

0.160 (0.408)

0.003 (0.987)

0.159 (0.409)

0–12

0.355 (0.089)

0.347 (0.097)

0.029 (0.893)

0.129 (0.549)

0.054 (0.803)

0.277 (0.190)

0.186 (0.386)

− 0.009 (0.968)

− 0.033 (0879)

0.071 (0.742)

0–24

0.400 (0.081)

0.141 (0.553)

0.458 (0.042)

0.542 (0.014)

0.045 (0.850)

0.323 (0.166)

0.276 (0.239)

0.518 (0.019)

0.648 (0.002)

0.565 (0.009)

IC

0

0.139 (0.320)

0.123 (0.379)

− 0.087 (0.535)

− 0.023 (0.870)

0.040 (0.776)

− 0.042 (0.765)

0.103 (0.464)

0.194 (0.164)

0.057 (0.687)

0.129 (0.358)

0–3

0.002 (0.989)

0.093 (0.575)

0.103 (0.533)

0.105 (0.524)

0.328 (0.042)

0.040 (0.847)

0.281 (0.084)

− 0.034 (0.839)

0.056 (0.734)

0.153 (0.352)

0–6

0.037 (0.848)

0.150 (0.439)

0.034 (0.863)

− 0.235 (0.238)

0.187 (0.332)

0.135 (0.485)

0.185 (0.336)

− 0.003 (0.988)

0.209 (0.276)

0.145 (0.452)

0–12

0.389 (0.060)

0.231 (0.277)

− 0.144 (0.502)

0.112 (0.603)

0.260 (0.221)

0.248 (0.242)

0.285 (0.177)

0.066 (0.760)

0.180 (0.401)

0.137 (0.524)

0–24

0.200 (0.412)

0.071 (0.774)

− 0.311 (0.195)

− 0.045 (0.857)

0.058 (0.813)

0.138 (0.572)

0.126 (0.608)

0.247 (0.308)

0.128 (0.602)

0.008 (0.976)

  1. SLEDAI-2K values including complement and centrally measured anti-dsDNA were used. In the first rows for each compartment, baseline autoantibody levels are compared with baselined SLEDAI-2K. In the following rows, changes in autoantibody levels in serum or IC during 3-, 6-, 12-, and 24-month follow-up and changes in SLEDAI-2K during the corresponding periods are compared. Spearman’s ρ coefficients are shown, with corresponding p values within brackets. Significant correlations are depicted in italics. Rib P ribosomal P
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us